Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Paratek Pharmaceuticals, Inc. PRTK NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
47/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Paratek Pharmaceuticals, Inc. (PRTK) — Analyst outlook / Analyst consensus target is. Based on 7 analyst ratings, the consensus is bullish — 5 Buy, 2 Hold.

PRTK Analyst Ratings

Buy
7
Ratings
5 Buy
2 Hold
Based on 7 analysts giving stock ratings to Paratek Pharmaceuticals, Inc. in the past 3 months
Rating breakdown
Buy
5 71%
Hold
2 29%
71%
Buy
5 analysts
29%
Hold
2 analysts
0%
Sell
0 analysts

People Also View

CRVS
CRVS
Corvus Pharmaceuticals, Inc.
$15.11
-0.92%
 ICVX
ICVX
Icosavax, Inc.
$15.31
-0.91%
 SELB
SELB
Selecta Biosciences, Inc.
$0.88
-8.00%
 IMMP
IMMP
Immutep Limited
$0.54
+72.81%
 ADAP
ADAP
Adaptimmune Therapeutics plc
$0.05
-3.00%
 EQ
EQ
Equillium, Inc.
$2.05
+6.77%
 LIAN
LIAN
LianBio
$0.32
-8.28%
 LPTX
LPTX
Leap Therapeutics, Inc.
$0.77
-3.15%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message